A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
← catalyst calendarNCT06876649 · readout ≤ 1,381 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
787estimated
Sites
38
Countries
Australia, France, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-20 | actual | When the study began enrolling |
| Primary completion | May 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
Intervention
- Drug: Pirtobrutinib — also filed as LOXO-305, LY3527727
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with a Grade ≥3 treatment-emergent AEs
measured Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed